Palliative Care Positively Affects Symptom Burden, QOL

Share this content:
Palliative Care Positively Affects Symptom Burden, QOL
Palliative Care Positively Affects Symptom Burden, QOL

WEDNESDAY, Nov. 23, 2016 (HealthDay News) -- Palliative care interventions are associated with improvements in patient quality of life and symptom burden, but do not affect survival, according to a review published in the Nov. 22/29 issue of the Journal of the American Medical Association.

Dio Kavalieratos, Ph.D., an assistant professor at the University of Pittsburgh School of Medicine's Section of Palliative Care and Medical Ethics, analyzed data from 43 clinical trials involving 12,731 adults with a serious illness and 2,479 of their family caregivers.

The researchers found that palliative care did provide clinically significant improvements in patients' quality-of-life burden at one-month and three-month follow-ups, based on evidence drawn from 15 applicable trials. The findings also showed that palliative care could reduce a patient's symptom burden at one and three months, but the evidence for this was weaker due to risk of bias in the studies. Palliative care was also associated with better advance care planning, patient and caregiver satisfaction with care, and lower utilization of health care resources.

There was mixed evidence regarding various other measures -- whether a patient died at home or in a hospital, how the care affected the mood of patients or caregivers, and whether it reduced overall health care expenditures. In addition, the pooled evidence did not support better quality of life or symptom management for patients at four to six months of follow-up. The team found no association between palliative care and survival (hazard ratio, 0.90; 95 percent confidence interval, 0.69 to 1.17).

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »